Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Immunotherapy

Addition of pembrolizumab to chemotherapy extends survival in advanced lung cancer

Results of a phase III lung cancer drug trial have shown an increased survival rate compared with the control group.

3D CT scan showing lung cancer

Source: K H Fung / Science Photo Library

The addition of pembrolizumab to induction therapy with pemetrexed and a platinum-based drug, and to pemetrexed maintenance therapy, resulted in significantly longer overall survival and progression-free survival for patients with advanced non-small-cell lung cancer, researchers find

Introducing first-line immunotherapy could benefit long-term outcomes in advanced non–small-cell lung cancer (NSCLC), a study has revealed[1].

In a phase III trial published in the New England Journal of Medicine (16 April 2018), researchers randomly assigned 616 patients with previously untreated metastatic non-squamous NSCLC without sensitising mutations to pemetrexed and a platinum-based drug, plus either 200mg of pembrolizumab or placebo, every three weeks for four cycles. This was followed by pembrolizumab or placebo for up to a total of 35 cycles plus pemetrexed maintenance therapy.

After a median follow-up of 10.5 months, the estimated overall survival in the pembrolizumab group was 69.2% compared with 49.4% in the placebo group. Median progression-free survival was 8.8 months in the pembrolizumab group and 4.9 months in the placebo group.

The addition of pembrolizumab did not appear to increase the frequency of adverse events.

The researchers concluded: “The addition of pembrolizumab to induction therapy with pemetrexed and a platinum-based drug, and to pemetrexed maintenance therapy, resulted in significantly longer overall survival and progression-free survival, and a higher response rate than the addition of placebo.”

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204908

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • 3D CT scan showing lung cancer

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.